Xifu Shang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xifu Shang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Xingshi Yuan
Department of Orthopedics, The First Affiliated Hospital of USTC, Hefei, China
9 shared publicationsZhi Li
Department of Orthopedics, The First Affiliated Hospital of USTC, Hefei, China
6 shared publicationsKerong Wu
Department of Orthopedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China
5 shared publications- Kun Chen
Department of Orthopaedic Surgery, University of California at Davis Medical School, Sacramento, CA, USA
5 shared publications - Chen Zhu
Department of Orthopedics, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
3 shared publications Mingyou Xu
Department of Orthopedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine
3 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- p. e70280
IGF2BP3 Overexpression Accelerates Osteoarthritis Progression by Promoting Glycolysis via m 6 A ‐Dependent Stabilization of ECM1 mRNA
N 6 ‐methyladenosine (m 6 A) plays a critical role in osteoarthritis (OA) pathogenesis. This study investigates the role of the m 6 A reader insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3) in OA progression. OA models were established in vivo through destabilization of the medial meniscus (DMM) surgery in mice and in vitro by stimulating primary chondrocytes with interleukin‐1β (IL‐1β). Cartilage destruction was assessed histopathologically. Chondrocyte viability, proliferation, and apoptosis were measured by CCK‐8, EdU, and flow cytometry, respectively. Inflammatory cytokine levels, lactate, glucose, and total m 6 A were quantified using commercial kits. Expression levels of IGF2BP3, extracellular matrix protein 1 (ECM1), ECM turnover markers, and glycolysis‐related genes were analyzed by RT‐qPCR, Western blot, immunohistochemistry, and immunofluorescence. Potential m 6 A modification sites in ECM1 transcripts were predicted using the SRAMP database, and IGF2BP3‐mediated, m 6 A‐dependent regulation of ECM1 was validated through RNA immunoprecipitation (RIP), MeRIP‐qPCR, and actinomycin D decay assays. Results revealed elevated levels of IGF2BP3, ECM1, m 6 A modification, and glycolytic activity in OA cartilage and IL‐1β‐treated chondrocytes. IGF2BP3 knockdown reversed IL‐1β‐induced reductions in chondrocyte viability and proliferation, suppressed apoptosis, decreased inflammatory cytokine secretion, attenuated ECM degradation, and reduced glycolytic flux in vitro, while also mitigating cartilage damage and matrix breakdown in vivo. Mechanistically, IGF2BP3 stabilized ECM1 mRNA in an m 6 A‐dependent manner, thereby modulating ECM1 expression. Restoration of ECM1 expression abolished the chondroprotective effects of IGF2BP3 knockdown against injury, inflammation, and enhanced glycolysis. In conclusion, IGF2BP3 enhances ECM1 expression via an m 6 A‐dependent pathway, thereby promoting glycolysis and exacerbating OA progression.
- 19 August 2026
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- p. e70280
Open AccessIGF2BP3 Overexpression Accelerates Osteoarthritis Progression by Promoting Glycolysis via m 6 A ‐Dependent Stabilization of ECM1 mRNA
N 6 ‐methyladenosine (m 6 A) plays a critical role in osteoarthritis (OA) pathogenesis. This study investigates the role of the m 6 A reader insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3) in OA progression. OA models were established in vivo through destabilization of the medial meniscus (DMM) surgery in mice and in vitro by stimulating primary chondrocytes with interleukin‐1β (IL‐1β). Cartilage destruction was assessed histopathologically. Chondrocyte viability, proliferation, and apoptosis were measured by CCK‐8, EdU, and flow cytometry, respectively. Inflammatory cytokine levels, lactate, glucose, and total m 6 A were quantified using commercial kits. Expression levels of IGF2BP3, extracellular matrix protein 1 (ECM1), ECM turnover markers, and glycolysis‐related genes were analyzed by RT‐qPCR, Western blot, immunohistochemistry, and immunofluorescence. Potential m 6 A modification sites in ECM1 transcripts were predicted using the SRAMP database, and IGF2BP3‐mediated, m 6 A‐dependent regulation of ECM1 was validated through RNA immunoprecipitation (RIP), MeRIP‐qPCR, and actinomycin D decay assays. Results revealed elevated levels of IGF2BP3, ECM1, m 6 A modification, and glycolytic activity in OA cartilage and IL‐1β‐treated chondrocytes. IGF2BP3 knockdown reversed IL‐1β‐induced reductions in chondrocyte viability and proliferation, suppressed apoptosis, decreased inflammatory cytokine secretion, attenuated ECM degradation, and reduced glycolytic flux in vitro, while also mitigating cartilage damage and matrix breakdown in vivo. Mechanistically, IGF2BP3 stabilized ECM1 mRNA in an m 6 A‐dependent manner, thereby modulating ECM1 expression. Restoration of ECM1 expression abolished the chondroprotective effects of IGF2BP3 knockdown against injury, inflammation, and enhanced glycolysis. In conclusion, IGF2BP3 enhances ECM1 expression via an m 6 A‐dependent pathway, thereby promoting glycolysis and exacerbating OA progression.
- Open Access
- 9 June 2026
- Published by Springer Nature in Arthroplasty
- Vol. 8 (1) , 46
Generalized joint hypermobility and functional recovery after THA for unilateral Hartofilakidis type C developmental dysplasia of the hip: a retrospective cohort study
Background: Generalized joint hypermobility (GJH) is common in developmental dysplasia of the hip (DDH) and may affect recovery after total hip arthroplasty (THA) for Hartofilakidis type C, but its impact on the trajectory of postoperative functional recovery in this severe subgroup has not been clearly characterized. Methods: We retrospectively reviewed patients aged 18–40 years who underwent THA for unilateral Hartofilakidis type C DDH (2018–2023). GJH was defined as a Beighton score ≥ 5. All procedures used a direct anterior approach with proximal femoral osteotomy for exposure and selective femoral shortening at the lesser trochanter level when reduction would otherwise impose excessive neurovascular tension or unacceptable residual leg-length discrepancy (LLD). Radiographic parameters and LLD were assessed. Harris Hip Score (HHS) was recorded preoperatively and at 1, 3, 6, and 12 months. Longitudinal HHS was analysed using a linear mixed-effects model; effect sizes were quantified by Cohen’s d and partial η 2 . Results: Fifty-eight patients were included (21 GJH, 37 non-GJH). Postoperative LLD was reduced without a between-group difference. Cup position at 6 months was similar; femoral offset tended to be higher in GJH ( p = 0.057). Femoral shortening distance was smaller in GJH ( p < 0.001). Observed HHS was lower in GJH at 1–6 months ( p < 0.001) but similar at 12 months. The linear mixed-effects model (LMM) showed significant time, group, and time × group effects ( p < 0.001). Adjusted between-group differences were largest at 1 month and progressively diminished, becoming non-significant at 12 months. One dislocation occurred in the GJH group; no revisions were required. Conclusions: In young adults with unilateral Hartofilakidis type C DDH, GJH did not compromise 12-month hip function after THA but was associated with a slower early recovery trajectory, with the largest deficit during the first 1–3 postoperative months.
- 9 June 2026
- Published by Springer Nature in Arthroplasty
- Vol. 8 (1) , 46
Open AccessGeneralized joint hypermobility and functional recovery after THA for unilateral Hartofilakidis type C developmental dysplasia of the hip: a retrospective cohort study
Background: Generalized joint hypermobility (GJH) is common in developmental dysplasia of the hip (DDH) and may affect recovery after total hip arthroplasty (THA) for Hartofilakidis type C, but its impact on the trajectory of postoperative functional recovery in this severe subgroup has not been clearly characterized. Methods: We retrospectively reviewed patients aged 18–40 years who underwent THA for unilateral Hartofilakidis type C DDH (2018–2023). GJH was defined as a Beighton score ≥ 5. All procedures used a direct anterior approach with proximal femoral osteotomy for exposure and selective femoral shortening at the lesser trochanter level when reduction would otherwise impose excessive neurovascular tension or unacceptable residual leg-length discrepancy (LLD). Radiographic parameters and LLD were assessed. Harris Hip Score (HHS) was recorded preoperatively and at 1, 3, 6, and 12 months. Longitudinal HHS was analysed using a linear mixed-effects model; effect sizes were quantified by Cohen’s d and partial η 2 . Results: Fifty-eight patients were included (21 GJH, 37 non-GJH). Postoperative LLD was reduced without a between-group difference. Cup position at 6 months was similar; femoral offset tended to be higher in GJH ( p = 0.057). Femoral shortening distance was smaller in GJH ( p < 0.001). Observed HHS was lower in GJH at 1–6 months ( p < 0.001) but similar at 12 months. The linear mixed-effects model (LMM) showed significant time, group, and time × group effects ( p < 0.001). Adjusted between-group differences were largest at 1 month and progressively diminished, becoming non-significant at 12 months. One dislocation occurred in the GJH group; no revisions were required. Conclusions: In young adults with unilateral Hartofilakidis type C DDH, GJH did not compromise 12-month hip function after THA but was associated with a slower early recovery trajectory, with the largest deficit during the first 1–3 postoperative months.
- Open Access
- 20 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e21927
Pearl‐Like Bioinspired Coating Enables Regulation of Mg Degradation for Osteoporotic Bone Repair
In osteoporotic bones, the stability of orthopedic implants is compromised, and excessive M1 macrophage polarization at the bone‐implant interface disrupts bone‐immune homeostasis, leading to implant loosening or failure. To address this, this study develops a bionic magnesium alloy internal fixation coating inspired by the “brick‐and‐mortar” structure of pearl, aiming to improve bone‐implant integration and vascularization in osteoporotic conditions. The multifunctional coating consists of a calcium phosphate (Ca‐P) “brick” layer, which serves as a mineralization template and corrosion barrier, and fibronectin‐mimetic peptides (Fn‐mimetic peptides) as the “mortar” to promote cell adhesion, regulate immune responses, and stimulate angiogenesis. This bionic multilayer structure not only alleviates oxidative stress in the osteoporotic microenvironment but also fosters immune regulation‐osteogenesis coupling and improves the bone‐vascular‐immune microenvironment. It precisely controls the degradation rate of Mg alloys and enhances tissue repair. The CaP layer reduces rapid degradation and prevents hydrogen gas release and local alkalinization, whereas Fn‐mimetic peptides enhance early bone integration and vascularization. The synergistic effect of the magnesium alloy implant and bionic coating significantly improved bone implant stability, regeneration, and vascularization, as demonstrated in osteoporotic rat models, offering a promising strategy for the design of bone repair materials under pathological conditions.
- 20 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e21927
Open AccessPearl‐Like Bioinspired Coating Enables Regulation of Mg Degradation for Osteoporotic Bone Repair
In osteoporotic bones, the stability of orthopedic implants is compromised, and excessive M1 macrophage polarization at the bone‐implant interface disrupts bone‐immune homeostasis, leading to implant loosening or failure. To address this, this study develops a bionic magnesium alloy internal fixation coating inspired by the “brick‐and‐mortar” structure of pearl, aiming to improve bone‐implant integration and vascularization in osteoporotic conditions. The multifunctional coating consists of a calcium phosphate (Ca‐P) “brick” layer, which serves as a mineralization template and corrosion barrier, and fibronectin‐mimetic peptides (Fn‐mimetic peptides) as the “mortar” to promote cell adhesion, regulate immune responses, and stimulate angiogenesis. This bionic multilayer structure not only alleviates oxidative stress in the osteoporotic microenvironment but also fosters immune regulation‐osteogenesis coupling and improves the bone‐vascular‐immune microenvironment. It precisely controls the degradation rate of Mg alloys and enhances tissue repair. The CaP layer reduces rapid degradation and prevents hydrogen gas release and local alkalinization, whereas Fn‐mimetic peptides enhance early bone integration and vascularization. The synergistic effect of the magnesium alloy implant and bionic coating significantly improved bone implant stability, regeneration, and vascularization, as demonstrated in osteoporotic rat models, offering a promising strategy for the design of bone repair materials under pathological conditions.
- Open Access
- 11 December 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 16 (6)
SERS detection of osteoarthritis-linked microRNA-204 via a DNAzyme-catalyzed self-amplifying circuit
- 11 December 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 16 (6)
Open AccessSERS detection of osteoarthritis-linked microRNA-204 via a DNAzyme-catalyzed self-amplifying circuit
- Open Access
- 23 October 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (11) , 2396-2409
Bioorthogonal Probe BTD-Az Enables Sensitive and Rapid In Vivo Profiling of Protein Cysteine Sulfenylation
Cysteine sulfenylation (Cys-SOH) is a transient redox-sensitive post-translational modification that regulates protein activity and cellular stress responses, yet its in vivo dynamics remain difficult to capture due to short half-life and low abundance. Here, we report the design and application of BTD-Az, a cell-permeable probe that incorporates an azide handle into the benzothiazine scaffold, enabling rapid bioorthogonal labeling of Cys-SOH both in vivo and in vitro, followed by efficient enrichment through strain-promoted azide-alkyne cycloaddition. This approach streamlines the detection and analysis of Cys-SOH with exceptional specificity and convenience. BTD-Az exhibited negligible cytotoxicity, efficiently enriched sulfenylated proteins in vitro, and achieved direct in vivo labeling in mouse tissues through SPAAC-mediated pull-down. Coupling BTD-Az with 4D-DIA proteomics allowed global sulfenylome profiling, revealing >5000 labeled proteins across tissues. As a proof-of-concept biological application, we applied BTD-Az to aging cartilage and identified 95 proteins with differential sulfenylation, including the mitochondrial enzyme IDH2, whose Cys-SOH modification promoted proteasomal degradation and exacerbated redox imbalance. Collectively, this study establishes BTD-Az as a robust chemical tool for in vivo sulfenylation profiling, providing a broadly applicable platform for redox proteomics and the discovery of redox-sensitive regulatory mechanisms in health and disease.
- 23 October 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (11) , 2396-2409
Open AccessBioorthogonal Probe BTD-Az Enables Sensitive and Rapid In Vivo Profiling of Protein Cysteine Sulfenylation
Cysteine sulfenylation (Cys-SOH) is a transient redox-sensitive post-translational modification that regulates protein activity and cellular stress responses, yet its in vivo dynamics remain difficult to capture due to short half-life and low abundance. Here, we report the design and application of BTD-Az, a cell-permeable probe that incorporates an azide handle into the benzothiazine scaffold, enabling rapid bioorthogonal labeling of Cys-SOH both in vivo and in vitro, followed by efficient enrichment through strain-promoted azide-alkyne cycloaddition. This approach streamlines the detection and analysis of Cys-SOH with exceptional specificity and convenience. BTD-Az exhibited negligible cytotoxicity, efficiently enriched sulfenylated proteins in vitro, and achieved direct in vivo labeling in mouse tissues through SPAAC-mediated pull-down. Coupling BTD-Az with 4D-DIA proteomics allowed global sulfenylome profiling, revealing >5000 labeled proteins across tissues. As a proof-of-concept biological application, we applied BTD-Az to aging cartilage and identified 95 proteins with differential sulfenylation, including the mitochondrial enzyme IDH2, whose Cys-SOH modification promoted proteasomal degradation and exacerbated redox imbalance. Collectively, this study establishes BTD-Az as a robust chemical tool for in vivo sulfenylation profiling, providing a broadly applicable platform for redox proteomics and the discovery of redox-sensitive regulatory mechanisms in health and disease.
- 11 April 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (19) , 5670-5685
Oxygen vacancy-containing hafnium-dioxide/polyetheretherketone composite with good photothermal performance and bioactivity for treatment of tumors and infection as well as the promotion of pro-osteogenesis
An oxygen vacancy-containing hafnium oxide/polyetheretherketone composite exhibits not only antitumor and antimicrobial properties because of its photothermal performance but also a pro-osteogenic effect both in vitro and in vivo .
- 11 April 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (19) , 5670-5685
Oxygen vacancy-containing hafnium-dioxide/polyetheretherketone composite with good photothermal performance and bioactivity for treatment of tumors and infection as well as the promotion of pro-osteogenesis
An oxygen vacancy-containing hafnium oxide/polyetheretherketone composite exhibits not only antitumor and antimicrobial properties because of its photothermal performance but also a pro-osteogenic effect both in vitro and in vivo .
- Open Access
- 4 March 2025
- Published by Elsevier in Materials Today Bio
- Vol. 31, 101629
Peptide-modified mesoporous silica nanoparticles for the coordinated regulation of macrophage polarization and pyroptosis in the treatment of implant-related infections
- 4 March 2025
- Published by Elsevier in Materials Today Bio
- Vol. 31, 101629
Open AccessPeptide-modified mesoporous silica nanoparticles for the coordinated regulation of macrophage polarization and pyroptosis in the treatment of implant-related infections
- Open Access
- 11 October 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (19) , 10732-10745
Micheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption
Osteoporosis is one of the major health problems characterized by decreased bone density and increased risk of fractures. Nowadays, the treating strategies against osteoporosis are efficient, but still have some drawbacks. Micheliolide, a guaianolide sesquiterpene lactone isolated from Michelia compressa and Michelia champac, has been reported to have anti-inflammatory effects. Here, our data suggest that Micheliolide could protect mice from ovariectomy induced bone loss. According to the Micro-CT scan and histomorphometry quantification data, Micheliolide treatment inhibits excessive osteoclast bone resorption without affecting bone formation in estrogen deficiency mice. Consistently, our data suggest that Micheliolide could inhibit osteoclastogenesis in vitro. Additionally, we confirmed that Micheliolide inhibits osteoclasts formation via inhibiting P38 MAPK signaling pathway, and P79350 (a P38 agonist) could rescue this effect. In summary, our data suggest that Micheliolide could ameliorate estrogen deficiency-induced bone loss via attenuating osteoclastogenesis. Hence, Micheliolide could be used as a novel anti-resorptive agent against osteoporosis.
- 11 October 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (19) , 10732-10745
Open AccessMicheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption
Osteoporosis is one of the major health problems characterized by decreased bone density and increased risk of fractures. Nowadays, the treating strategies against osteoporosis are efficient, but still have some drawbacks. Micheliolide, a guaianolide sesquiterpene lactone isolated from Michelia compressa and Michelia champac, has been reported to have anti-inflammatory effects. Here, our data suggest that Micheliolide could protect mice from ovariectomy induced bone loss. According to the Micro-CT scan and histomorphometry quantification data, Micheliolide treatment inhibits excessive osteoclast bone resorption without affecting bone formation in estrogen deficiency mice. Consistently, our data suggest that Micheliolide could inhibit osteoclastogenesis in vitro. Additionally, we confirmed that Micheliolide inhibits osteoclasts formation via inhibiting P38 MAPK signaling pathway, and P79350 (a P38 agonist) could rescue this effect. In summary, our data suggest that Micheliolide could ameliorate estrogen deficiency-induced bone loss via attenuating osteoclastogenesis. Hence, Micheliolide could be used as a novel anti-resorptive agent against osteoporosis.
- Open Access
- 1 September 2023
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 55 (9) , 2051-2066
CircFam190a: a critical positive regulator of osteoclast differentiation via enhancement of the AKT1/HSP90β complex
The identification of key regulatory factors that control osteoclastogenesis is important. Accumulating evidence indicates that circular RNAs (circRNAs) are discrete functional entities. However, the complexities of circRNA expression as well as the extent of their regulatory functions during osteoclastogenesis have yet to be revealed. Here, based on circular RNA sequencing data, we identified a circular RNA, circFam190a, as a critical regulator of osteoclast differentiation and function. During osteoclastogenesis, circFam190a is significantly upregulated. In vitro, circFam190a enhanced osteoclast formation and function. In vivo, overexpression of circFam190a induced significant bone loss, while knockdown of circFam190a prevented pathological bone loss in an ovariectomized (OVX) mouse osteoporosis model. Mechanistically, our data suggest that circFam90a enhances the binding of AKT1 and HSP90β, promoting AKT1 stability. Altogether, our findings highlight the critical role of circFam190a as a positive regulator of osteoclastogenesis, and targeting circFam190a might be a promising therapeutic strategy for treating pathological bone loss.
- 1 September 2023
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 55 (9) , 2051-2066
Open AccessCircFam190a: a critical positive regulator of osteoclast differentiation via enhancement of the AKT1/HSP90β complex
The identification of key regulatory factors that control osteoclastogenesis is important. Accumulating evidence indicates that circular RNAs (circRNAs) are discrete functional entities. However, the complexities of circRNA expression as well as the extent of their regulatory functions during osteoclastogenesis have yet to be revealed. Here, based on circular RNA sequencing data, we identified a circular RNA, circFam190a, as a critical regulator of osteoclast differentiation and function. During osteoclastogenesis, circFam190a is significantly upregulated. In vitro, circFam190a enhanced osteoclast formation and function. In vivo, overexpression of circFam190a induced significant bone loss, while knockdown of circFam190a prevented pathological bone loss in an ovariectomized (OVX) mouse osteoporosis model. Mechanistically, our data suggest that circFam90a enhances the binding of AKT1 and HSP90β, promoting AKT1 stability. Altogether, our findings highlight the critical role of circFam190a as a positive regulator of osteoclastogenesis, and targeting circFam190a might be a promising therapeutic strategy for treating pathological bone loss.
- 20 July 2023
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 37 (7) , 3911-3919
Micheliolide Inhibits Interleukin-1β-Induced Inflammation by Downregulating MAPK in Chondrocytes
Background: Micheliolide (MCL) has ameliorating effects on tissue inflammation, but its potential therapeutic effect on osteoarthritis (OA) is unknown. The study aims to explore the pharmacological action and mechanism of MCL in the treatment of OA. Methods: Two models of OA were established and treated with MCL. Chondrocyte activity was evaluated by cell counting kit (CCK)-8 assay, while prostaglandin E2 (PGE2), nitric oxide (NO), and interleukin-1β (IL-1β) levels were measured using commercial kits. Mitogen activated protein kinase (MAPK) pathway-related proteins were evaluated by Western blotting, while key enzymes in cartilage degradation were analyzed by real-time quantitative polymerase chain reaction. Cartilage injury in OA mice was assessed by Saffranine O green staining, whereas pathological injury of brain, lung, kidney, and heart was determined by hematoxylin-eosin staining. Results: MCL suppressed the production of IL-1β-induced PGE2 and NO, cyclooxygenase 2, and inducible nitric oxide synthase in mouse chondrocytes. MCL also inhibited IL-1β-induced disintegrin and metalloproteinase with thrombospondin motif 4/5 mRNA and matrix metalloproteinases. MAPK pathway was inhibited by MCL. MCL effectively inhibited OA in mice. Conclusions: MCL inhibits IL-1β-stimulated chondrocyte inflammation by blocking the MAPK pathway. The application of MCL in the treatment of OA provides new data support.
- 20 July 2023
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 37 (7) , 3911-3919
Micheliolide Inhibits Interleukin-1β-Induced Inflammation by Downregulating MAPK in Chondrocytes
Background: Micheliolide (MCL) has ameliorating effects on tissue inflammation, but its potential therapeutic effect on osteoarthritis (OA) is unknown. The study aims to explore the pharmacological action and mechanism of MCL in the treatment of OA. Methods: Two models of OA were established and treated with MCL. Chondrocyte activity was evaluated by cell counting kit (CCK)-8 assay, while prostaglandin E2 (PGE2), nitric oxide (NO), and interleukin-1β (IL-1β) levels were measured using commercial kits. Mitogen activated protein kinase (MAPK) pathway-related proteins were evaluated by Western blotting, while key enzymes in cartilage degradation were analyzed by real-time quantitative polymerase chain reaction. Cartilage injury in OA mice was assessed by Saffranine O green staining, whereas pathological injury of brain, lung, kidney, and heart was determined by hematoxylin-eosin staining. Results: MCL suppressed the production of IL-1β-induced PGE2 and NO, cyclooxygenase 2, and inducible nitric oxide synthase in mouse chondrocytes. MCL also inhibited IL-1β-induced disintegrin and metalloproteinase with thrombospondin motif 4/5 mRNA and matrix metalloproteinases. MAPK pathway was inhibited by MCL. MCL effectively inhibited OA in mice. Conclusions: MCL inhibits IL-1β-stimulated chondrocyte inflammation by blocking the MAPK pathway. The application of MCL in the treatment of OA provides new data support.